- Home
- INCR
INCR
Intercure Ltd.
as 01-17-2025 4:00pm EST
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.
| Founded: | 1994 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 76.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 43.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.38 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.17 - $3.72 | Next Earning Date: | 02-15-2025 |
| Revenue: | $72,420,918 | Revenue Growth: | -34.26% |
| Revenue Growth (this year): | -18.24% | Revenue Growth (next year): | 39.30% |
Latest Intercure Ltd. News
INCR Breaking Stock News: Dive into INCR Ticker-Specific Updates for Smart Investing
PR Newswire
a month ago
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
Market Exclusive
5 months ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
GlobeNewswire
5 months ago
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
MT Newswires
5 months ago
InterCure Partners with Cookies to Launch Branded Products in Germany
Business Wire
5 months ago
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
CNW Group
7 months ago
Lotto 6/49 - $64 million up for grabs in the next draw!
Simply Wall St.
7 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
7 months ago
Seoul says it will resume loudspeaker propaganda against North
Compare INCR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INCR Intercure Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.